1. Egészségügyi Minisztérium Szakmai Protokollja. Portális hypertensio. Készítette: Sebészeti Szakmai Kollégium 2007. http://www.eum.hu/seb-portalis-pdf.

2. DL Shawcross Y Sharifi JB Canavan AD Yeoman et al.2011 Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis J Hepatology 54 640 9.

2. DL Shawcross Y Sharifi JB Canavan AD Yeoman 2011 Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis J Hepatology 54 640 9.)| false
• Search Google Scholar
• Export Citation

3. B Als-Nielsen LL Gluud C Gluud 2004 Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials BMJ 328 1046 50.

3. B Als-Nielsen LL Gluud C Gluud 2004 Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials BMJ 328 1046 50.)| false
• Search Google Scholar
• Export Citation

4. P Blanc JP Daures JM Rouillon et al.1992 Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis Hepatology 15 222 8.

4. P Blanc JP Daures JM Rouillon 1992 Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta-analysis Hepatology 15 222 8.)| false
• Search Google Scholar
• Export Citation

5. F Orlandi U Freddara MT Candelaresi et al.1981 Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study Dig Dis Sci 26 498 506.

5. F Orlandi U Freddara MT Candelaresi 1981 Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: A randomized clinical study Dig Dis Sci 26 498 506.)| false
• Search Google Scholar
• Export Citation

6. NM Bass KD Mullen A Sanyal F Poordad et al.2010 Rifaximin Treatment in Hepatic Encephalopathy N Eng Med J 362 1071 81.

6. NM Bass KD Mullen A Sanyal F Poordad 2010 Rifaximin Treatment in Hepatic Encephalopathy N Eng Med J 362 1071 81.)| false
• Search Google Scholar
• Export Citation

7. F Szalay L Telegdy D Szeli T Csák A Folhoffer A Horváth et al.2004 Rifaximin a hepaticus encephalopathia kezelésében LAM 14 321 5.

7. F Szalay L Telegdy D Szeli T Csák A Folhoffer A Horváth 2004 Rifaximin a hepaticus encephalopathia kezelésében LAM 14 321 5.)| false
• Search Google Scholar
• Export Citation

8. P Massa E Vallerino M Dodero 1993 Treatment of hepatic encephalopathy with rifaximin: Double blind, double dummy study versus lactulose Eur J Clin Res 4 4 18.

8. P Massa E Vallerino M Dodero 1993 Treatment of hepatic encephalopathy with rifaximin: Double blind, double dummy study versus lactulose Eur J Clin Res 4 4 18.)| false
• Search Google Scholar
• Export Citation

9. PS Mantry S Munsaf 2010 Rifaximine for the Treatment of Hepatic Encephalopathy Transpl Proc 42 4543 7.

9. PS Mantry S Munsaf 2010 Rifaximine for the Treatment of Hepatic Encephalopathy Transpl Proc 42 4543 7.)| false
• Search Google Scholar
• Export Citation

10. LW Teperman VP Peyregne 2010 Considerations on the Impact of Hepatic Encephalopathy Treatments in the Pretransplant Setting Transplantation 89 771 8.

10. LW Teperman VP Peyregne 2010 Considerations on the Impact of Hepatic Encephalopathy Treatments in the Pretransplant Setting Transplantation 89 771 8.)| false
• Search Google Scholar
• Export Citation

11. G Kircheis R Nilius C Held et al.1997 Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study Hepatology 25 1351 60.

11. G Kircheis R Nilius C Held 1997 Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study Hepatology 25 1351 60.)| false
• Search Google Scholar
• Export Citation

12. S Stauch G Kircheis G Adler et al.1998 Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo- controlled double-blind study J Hepatol 28 856 64.

12. S Stauch G Kircheis G Adler 1998 Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo- controlled double-blind study J Hepatol 28 856 64.)| false
• Search Google Scholar
• Export Citation

13. T Hassanein F Tofteng R Brown B McGuire P Lynch et al.2004 Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of Hepatic Encephalopathy: A Prospective, Controlled, Randomized Multicenter Trial Hepatology 40 726 7.

13. T Hassanein F Tofteng R Brown B McGuire P Lynch 2004 Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of Hepatic Encephalopathy: A Prospective, Controlled, Randomized Multicenter Trial Hepatology 40 726 7.)| false
• Search Google Scholar
• Export Citation

14. T Hassanein F Tofteng RS Brown B McGuire P Lynch et al.2007 Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis Hepatology 46 1853 62.

14. T Hassanein F Tofteng RS Brown B McGuire P Lynch 2007 Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis Hepatology 46 1853 62.)| false
• Search Google Scholar
• Export Citation

15. L Szalay 2004 Hepaticus encephalopathia korszerű kezelése Orv Hetil 34 1747 52.

15. L Szalay 2004 Hepaticus encephalopathia korszerű kezelése Orv Hetil 34 1747 52.)| false
• Search Google Scholar
• Export Citation

16. EASL Annual report 2010. http://www.easl.eu/assets/application/annual/docs/e96ef94a666b02c_file.pdf.